Search results for "Human medicine"

showing 10 items of 256 documents

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for th…

2020

Background: Across low-income and middle-income countries (LMICs), one in ten deaths in children younger than 5 years is attributable to diarrhoea. The substantial between-country variation in both diarrhoea incidence and mortality is attributable to interventions that protect children, prevent infection, and treat disease. Identifying subnational regions with the highest burden and mapping associated risk factors can aid in reducing preventable childhood diarrhoea. Methods: We used Bayesian model-based geostatistics and a geolocated dataset comprising 15 072 746 children younger than 5 years from 466 surveys in 94 LMICs, in combination with findings of the Global Burden of Diseases, Injuri…

Low income countriesmedicine.medical_treatment030204 cardiovascular system & hematologyGlobal HealthTHERAPYGlobal Burden of Disease0302 clinical medicinePrevalenceGlobal healthMedicineWATER030212 general & internal medicineChildren11 Medical and Health SciencesIncidenceMortality rateIncidence (epidemiology)1. No povertyGeneral Medicine3142 Public health care science environmental and occupational healthDiarrhoea3. Good healthChild PreschoolMiddle income countriesA990 Medicine and Dentistry not elsewhere classifiedTERRITORIESLife Sciences & BiomedicineInfantsDiarrheaAFRICAmedicine.medical_specialtyChildhood deathsRJsanitationDeveloping countryChildhood diarrhoeal morbidityITC-HYBRID03 medical and health sciencesMedicine General & InternalGeneral & Internal MedicineEnvironmental healthSYSTEMATIC ANALYSISLife ScienceHumansHealthcare DisparitiesOral rehydration therapyRisk factorhand washingDeveloping CountriesDisease burdenGlobal NutritionWereldvoedingScience & TechnologySEX-SPECIFIC MORTALITYbusiness.industryCHOLERAPublic healthBayes Theoremdiarrheal diseaseLocal Burden of Disease Diarrhoea CollaboratorsITC-ISI-JOURNAL-ARTICLENAHuman medicineDiarreabusiness
researchProduct

Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study

2021

We aimed to determine the impact of pre-operative isolation on postoperative pulmonary complications after elective surgery during the global SARS-CoV-2 pandemic. We performed an international prospective cohort study including patients undergoing elective surgery in October 2020. Isolation was defined as the period before surgery during which patients did not leave their house or receive visitors from outside their household. The primary outcome was postoperative pulmonary complications, adjusted in multivariable models for measured confounders. Pre-defined sub-group analyses were performed for the primary outcome. A total of 96,454 patients from 114 countries were included and overall, 26…

Lung DiseasesMaleInternationalitySARS-Cov-2 ; COVID-19 ; surgery ; pathways ; pre-operative isolationSettore MED/18 - CHIRURGIA GENERALEVascular damage Radboud Institute for Health Sciences [Radboudumc 16]pathwaysLung DiseaseESTUDOS PROSPECTIVOSCohort StudiesPatient IsolationsurgeryPostoperative Complications80 and overProspective StudiesProspective cohort study610 Medicine & healthAged 80 and overSARS-Cov-2; COVID-19; surgery; pathways; pre-operative isolationIncidence (epidemiology)Treatment OutcomeElective Surgical ProceduresFemaleElective Surgical ProcedureCohort studyHumanpre-operative isolationmedicine.medical_specialtyIsolation (health care)SARS-Cov-2Preoperative careNOCOVID-19; SARS-Cov-2; pathways; pre-operative isolation; surgeryAnesthesiologyPreoperative CaremedicineHumansElective surgeryLS7_4AgedElective Surgical Procedurebusiness.industrypathwayCOVID-19SurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Prospective StudieAnesthesiology and Pain MedicineHuman medicinePostoperative ComplicationCohort Studiebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

2014

Abstract: Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, even in long-lasting responses, resistance to EGFR TKIs invariably occurs. Areas covered: This review examines resistance mechanisms to EGFR TKI treatment, which mainly arise from secondary EGFR mutations. Other resistance-inducing processes include mesenchymal-epithelial transition factor (MET) amplification, epithelial-mesenchymal transformation, phenotypic change from NSCLC to small-cell lung carcinoma, and modifications in parallel signalling pathways. Current…

Lung NeoplasmsSettore MED/06 - Oncologia MedicaAfatinibNovel therapeutic strategiesLapatinibmedicine.disease_causeNSCLCT790Mchemistry.chemical_compoundErbB ReceptorsCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansRadiology Nuclear Medicine and imagingEpidermal growth factor receptorProtein Kinase InhibitorsEGFR inhibitorsbiologybusiness.industryEGFR mutations; TKI inhibitors resistance; NSCLC; New drugs; Novel therapeutic strategiesGeneral MedicineNew drugEGFR mutationsCombined Modality TherapyDacomitinibrespiratory tract diseasesErbB ReceptorsNew drugsOncologychemistryDrug Resistance NeoplasmCancer researchbiology.proteinKRASHuman medicineEGFR mutationbusinessmedicine.drugTKI inhibitors resistanceCancer Treatment Reviews
researchProduct

BRAF mutations in non-small cell lung cancer : has finally Janus opened the door?

2016

Abstract: B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate a permanent activation of the mitogen activated protein kinase (MAPK) pathway, which promotes tumor growth and proliferation. In the present review, we discuss B-Raf mutation epidemiology, diagnostic methods to detect B-Raf mutations, the role of B-Raf as a driver mutation and a potential therapeutic target in NSCLC. The results of clinical trials involving B-Raf or MAPK pathway inhibitors for the treatment of NSCLC are also discussed. Clinical trials evaluating B-Raf inhibitors in BRAF mutated NSCLC patients have shown promising results, and larger prospective studies are warrante…

MAPK/ERK pathwayProto-Oncogene Proteins B-rafmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentCellProtein Kinase Inhibitormedicine.disease_causeBioinformaticsNSCLCTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineHumans030212 general & internal medicineB-Raf inhibitorLung cancerProtein Kinase InhibitorsB-Raf inhibitorsMutationHematologybiologybusiness.industryB-RafB-Raf; B-Raf inhibitors; Drug; Mutation; NSCLC; Oncology; Hematology; Geriatrics and GerontologyHematologymedicine.diseaseLung NeoplasmClinical trialmedicine.anatomical_structureOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMitogen-activated protein kinaseMutationbiology.proteinCancer researchHuman medicineDrugGeriatrics and GerontologybusinessHumanCritical reviews in oncology, hematology
researchProduct

NBEA : developmental disease gene with early generalized epilepsy phenotypes

2018

Abstract: NBEA is a candidate gene for autism, and de novo variants have been reported in neurodevelopmental disease (NDD) cohorts. However, NBEA has not been rigorously evaluated as a disease gene, and associated phenotypes have not been delineated. We identified 24 de novo NBEA variants in patients with NDD, establishing NBEA as an NDD gene. Most patients had epilepsy with onset in the first few years of life, often characterized by generalized seizure types, including myoclonic and atonic seizures. Our data show a broader phenotypic spectrum than previously described, including a myoclonic-astatic epilepsy-like phenotype in a subset of patients. Ann Neurol 2018;84:796-803

Male0301 basic medicineCarrier Proteins/geneticsCandidate geneDiseaseNeurodevelopmental Disorders/geneticsEpilepsy0302 clinical medicineNerve Tissue Proteins/geneticsChildAtonic seizureGeneticsddc:618PhenotypePhenotypeNeurologyChild PreschoolEpilepsy GeneralizedFemaleNEUROBEACHINRare cancers Radboud Institute for Health Sciences [Radboudumc 9]AdolescentGenotypeGeneralized/geneticsNerve Tissue ProteinsBiologyPATIENTArticle03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CentermedicineJournal ArticleHumansGeneralized epilepsyAUTISMPreschoolGeneSPECTRUMNeurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]EpilepsyDELETIONNBEA encodes neurobeachinmedicine.diseaseFRAMEWORK030104 developmental biology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsNeurodevelopmental DisordersDE-NOVO MUTATIONSMutationAutismNeurology (clinical)Human medicineCarrier Proteins030217 neurology & neurosurgeryAnnals of neurology
researchProduct

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR…

2017

BACKGROUND: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different classes of targeted agents in patients with KRAS wild-type (wt) or RAS wt mCRC suggest that primary tumour location (side), might be both prognostic and predictive for clinical outcome. METHODS: This retrospective analysis investigated the prognostic and predictive influence of the localization of the primary tumour in patients with unresectable RAS wt mCRC included in six randomized trials (CRY…

Male0301 basic medicineOncologyColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeEGFR Antibody0302 clinical medicineAntineoplastic Agents ImmunologicalNeoplasias ColorrectaisMedicineNeoplasm MetastasisRandomized Controlled Trials as Topicpredictive valuePanitumumabHazard ratiotumour sideAntibodies MonoclonalHematologyPrognosisChemotherapy regimenErbB ReceptorsBevacizumabTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleKRASColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyBevacizumabcolorectal cancerGenes ras03 medical and health sciencesAnticorpos MonoclonaisInternal medicineHumansChemotherapybusiness.industryAntineoplásicos ImunológicosOdds ratiomedicine.diseaserandomised trial030104 developmental biologyGenes rasHuman medicinebusinessprognosticanti-EGFR treatment
researchProduct

The landscape of epilepsy-related GATOR1 variants

2019

Purpose:\ud \ud To define the phenotypic and mutational spectrum of epilepsies related to DEPDC5, NPRL2 and NPRL3 genes encoding the GATOR1 complex, a negative regulator of the mTORC1 pathway.\ud \ud Methods:\ud \ud We analyzed clinical and genetic data of 73 novel probands (familial and sporadic) with epilepsy-related variants in GATOR1-encoding genes and proposed new guidelines for clinical interpretation of GATOR1 variants.\ud \ud Results:\ud \ud The GATOR1 seizure phenotype consisted mostly in focal seizures (e.g., hypermotor or frontal lobe seizures in 50%), with a mean age at onset of 4.4 years, often sleep-related and drug-resistant (54%), and associated with focal cortical dysplasia…

Male0301 basic medicineProbandDEPDC5SUDEP030105 genetics & heredityBioinformaticsLoss of Function Mutation/geneticsEpilepsyINDEL MutationLoss of Function MutationmTORC1 pathwayGenetics(clinical)ChildGenetics (clinical)Multiprotein Complexes/geneticsBrugada SyndromeDNA Copy Number VariationBrugada syndromeINDEL Mutation/geneticsGTPase-Activating ProteinsNPRL3SeizureDEPDC5PhenotypePedigree3. Good healthBrugada Syndrome/geneticsChild PreschoolFemaleHumanSignal TransductionDNA Copy Number VariationsAdolescentSeizures/complicationsMechanistic Target of Rapamycin Complex 1/geneticsDNA Copy Number Variations/geneticsMechanistic Target of Rapamycin Complex 1Tumor Suppressor Proteins/geneticsArticleFocal cortical dysplasia03 medical and health sciencesSeizuresGTPase-Activating Proteins/geneticsmedicineHumansGenetic Predisposition to DiseaseDEPDC5; Focal cortical dysplasia; Genetic focal epilepsy; mTORC1 pathway; SUDEPGenetic focal epilepsyEpilepsy/complicationsRepressor Proteins/geneticsEpilepsybusiness.industryGTPase-Activating ProteinTumor Suppressor ProteinsInfant NewbornCorrectionInfantRepressor ProteinCortical dysplasiamedicine.diseaseddc:616.8Repressor Proteins030104 developmental biologyFrontal lobe seizures[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsMultiprotein ComplexesMultiprotein ComplexeSignal Transduction/geneticsHuman medicinebusiness
researchProduct

Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA)

2019

Abstract.Gunduz C, Basoglu OK, Hedner J, et al; onbehalf of the European Sleep Apnoea Databasecollaborators (Biruni University; Ege University;Gothenburg University; Sahlgrenska UniversityHospital; University of Palermo; CNR Institute ofBiomedicine and Molecular Immunology; St. AdolfStift; Hospital de Santa Maria; University of Crete;Antoine-Beclere Hospital; G. PapanikolaouHospital; Institute of Tuberculosis and LungDiseases; University Hospital Brno; St. Ann’sUniversity Hospital; Universite ́ Grenoble Alpes)Hyperlipidaemia prevalence and cholesterolcontrol in obstructive sleep apnoea: Data from theEuropean sleep apnea database (ESADA).J InternMed2019;286: 676–688.Background and objective.…

Male0301 basic medicine[SDV]Life Sciences [q-bio]PolysomnographyHyperlipidemiasSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologycomputer.software_genre03 medical and health sciences0302 clinical medicineRisk FactorsDiabetes mellitusPrevalenceInternal MedicineHumansMedicinecholesterol ; hyperlipidaemia ; hypoxia ; obesity ; sleep apnoea.ObesitySleep Apnea ObstructiveDatabasehyperlipidaemiahypoxiabusiness.industryConfoundingcholesterolSleep apneaOdds ratioMiddle Agedmedicine.diseaseObesityrespiratory tract diseases[SDV] Life Sciences [q-bio]EuropeCross-Sectional Studies030104 developmental biologyQuartileCardiovascular DiseasesCohortFemaleHuman medicinebusinesssleep apnoeaBody mass indexcomputer
researchProduct

Global, regional, and national burden of stroke and its risk factors, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

2021

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]…

MaleAging030204 cardiovascular system & hematologyStroke dataGUIDELINES3124 Neurology and psychiatryBody Mass IndexGlobal Burden of Disease0302 clinical medicineRA0421Risk FactorsEpidemiologyStrokesYOUNG-ADULTSPrevalence80 and overAetiology610 Medicine & healthStrokePOPULATION1103 Clinical Sciences 1109 NeurosciencesCause of deathAged 80 and overeducation.field_of_studyMortality rateIncidence (epidemiology)Incidence1. No povertyArticlesHälsovetenskaperMiddle AgedStroke typesddc:3. Good healthStrokeISCHEMIC-STROKEIncomeFemaleQuality-Adjusted Life YearsLife Sciences & BiomedicineAdultmedicine.medical_specialtyGBDPopulationClinical SciencesClinical Neurology610 Medicine & health03 medical and health sciencesClinical ResearchMIDDLE-INCOME COUNTRIESHealth SciencesmedicineHumansRisk factoreducationGBD 2019 Stroke CollaboratorsCerebral HemorrhageAgedIschemic StrokeGlobal burdenScience & TechnologyNeurology & NeurosurgeryHYPERTENSIONbusiness.industryMORTALITYPrevention3112 NeurosciencesNeurosciences1103 Clinical SciencesSERVICESSubarachnoid Hemorrhagemedicine.diseasePREVENTIONBrain DisordersGood Health and Well BeingAttributable riskHuman medicineNeurology (clinical)Neurosciences & Neurologybusiness1109 Neurosciences030217 neurology & neurosurgeryDemography2.4 Surveillance and distributionRC
researchProduct

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

2018

© 2018 Elsevier Inc.

MaleAls geneGenome-wide association studyFAMILIAL ALSALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS0302 clinical medicine80 and overPsychologyGWASKIF5AAetiologycargoAged 80 and over0303 health sciencesFrench ALS ConsortiumKinesinKINESIN HEAVY-CHAINCognitive Sciencesaxonal transportHumanHereditary spastic paraplegiaNeuroscience(all)Single-nucleotide polymorphismTARGETED DISRUPTIONArticle03 medical and health sciencesGeneticsHumansAmino Acid SequenceLoss functionAgedHEXANUCLEOTIDE REPEATNeuroscience (all)MUTATIONSAmyotrophic Lateral Sclerosis3112 Neurosciences1702 Cognitive Sciencemedicine.diseaseITALSGEN ConsortiumAnswer ALS Foundation030104 developmental biologyALS Sequencing ConsortiumHuman medicine1109 Neurosciences030217 neurology & neurosurgery0301 basic medicineALS; GWAS; KIF5A; WES; WGS; axonal transport; cargo[SDV]Life Sciences [q-bio]KinesinsNeurodegenerativeGenetic analysisGenomeAMYOTROPHIC-LATERAL-SCLEROSIS3124 Neurology and psychiatryCohort StudiesPathogenesisLoss of Function MutationMissense mutation2.1 Biological and endogenous factorsAmyotrophic lateral sclerosisNYGC ALS ConsortiumGeneticsGeneral NeuroscienceALS axonal transport cargo GWAS KIF5A WES WGSMiddle AgedPhenotypeSettore MED/26 - NEUROLOGIANeurologicalProject MinE ALS Sequencing ConsortiumKinesinWESFemaleAdultBiologyGENOTYPE IMPUTATIONALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS; Adult; Aged; Aged 80 and over; Amino Acid Sequence; Amyotrophic Lateral Sclerosis; Cohort Studies; Female; Genome-Wide Association Study; Humans; Kinesin; Loss of Function Mutation; Male; Middle Aged; Young AdultNOYoung AdultRare DiseasesmedicineSLAGEN ConsortiumGene030304 developmental biologyClinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) ConsortiumNeurology & NeurosurgeryHuman GenomeNeurosciencesAXONAL-TRANSPORTBrain DisordersALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS;Family memberDNA-DAMAGEMOTOR-NEURONS3111 BiomedicineCohort StudieALSGenomic Translation for ALS Care (GTAC) ConsortiumWGSAmyotrophic Lateral SclerosiGenome-Wide Association StudyALS; axonal transport; cargo; GWAS; KIF5A; WES; WGS; Neuroscience (all)
researchProduct